Articles On Pharmaust (ASX:PAA)

S&P 500 at record high again All three US stock market benchmarks were higher on Tuesday, bolstered by the Biden-Xi virtual meeting. S&P 500 rose by 0.51% and closed at record level again, while the Dow Jones and tech-heavy Nasdaq w...

PharmAust (ASX:PAA) has signed agreements with Veterinary Specialists Auckland and Intuit Regulatory to expand its canine Phase 2b lymphoma studies into New Zealand.

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

The expansion of PharmAust’s Phase 2b studies in New Zealand is the first step towards launching a Phase 3 clinical trial of monepantel as a cancer treatment in dogs. Clinical stage biotech company, PharmAust (ASX:PAA), is moving fast towar...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

PharmAust (PAA) signs agreements to expand its canine lymphoma studies into New Zealand A deal has been penned with Veterinary Specialists Auckland and Intuit Regulatory to expand PharmAust’s Phase 2b lymphoma studies, in preparation for a...

PharmAust is conducting multiple studies on lead drug monepantel, as it looks to commercialise the drug for multiple applications. Clinical stage biotech company, PharmAust (ASX:PAA), continued to make progress in the September quarter – ad...

After completing MPL demonstration batch manufacture, PharmAust is now preparing for clinical trials of its lead drug Monepantel in COVID-19 and Motor Neurone Disease treatments. Clinical stage biotech company, PharmAust (ASX:PAA) is makin...

PharmAust (PAA) has reached out to COVID-19 trial sites following production of a demonstration batch of monepantel A 500 gram demonstration batch of PharmAust’s anticancer treatment has been produced and was shown to have a greater purity...

Highlights ASX 200 continued to trade in green on Tuesday despite losses in metals & mining shares. The Australian market saw broad-based buying activities, tracking positive cues from Wall Street amid easing inflation fears. Inve...

Highlights Before COVID-19 struck, Australian families were spending over 10% of their weekly household budget on leisure and recreation. However, nearly two-year-long restrictions imposed due to the coronavirus pandemic put brakes on...

PharmAust (ASX:PAA) has provided an update on its Phase 2b trial testing the anti-cancer activity of monepantel in pet dogs with B-cell lymphoma.

Highlights Australian shares are expected to give away most of Monday’s gains after latest Chinese data showed slower-than-expected growth in its last quarter. The domestic shares may also fall on Tuesday, likely hurt by losses in mine...

After encouraging results from Phase 2 trials, PharmAust is now getting ready for a Phase 3 trial of its lead drug monepantel on the way to potential commercialisation. Clinical stage biotech company, PharmAust (ASX:PAA), is one step closer...

It’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for investors to digest. But the Health Index (XHJ) is trading down by 0.5% at the time of writing, compared to the broader index which is trading...

Wall Street advances on strong earnings US stocks advanced on Friday on strong corporate earnings which were highlighted by record investment banking fees. Goldman Sachs’s beat analysts’ expectations and pulled in US$3.7bn in M&A adviso...

The recent breakthrough in the US on antiviral molnupiravir has shone the spotlight on PharmAust’s own testing of lead drug, monepantel. In a major development last week, US-based Merck and partner Ridgeback Biotherapeutics have called for...

The options offering will give loyal shareholders the opportunity to cash in on PharmAust’s success over the next two years. Clinical stage biotech company, PharmAust (ASX:PAA), is giving shareholders the opportunity to participate in a loy...

Epichem’s novel technology that converts waste to energy is a game changer, and will take the company and parent PharmAust into the multi-billion dollar bioplastics and bio-ethanol energy markets.  In early August, clinical stage biotech co...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

PharmAust is set to benefit from Epichem’s debt repayment with an expected improvement to the bottom line, as it begins to leverage the state-of-the-art laboratories in Technology Park, WA. Clinical stage biotech company, PharmAust (ASX:PAA...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

The completion of the flow reactor will potentially take PharmAust into the multi-billion dollar bioplastics and bio-ethanol markets. Clinical stage biotech company, PharmAust (ASX:PAA), has reached a critical milestone in its efforts to de...

ASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by 0.19%. A class action proceeding against Mayne Pharma (ASX:MYX) has been brought by Phi Finney McDonald on behalf on investors who bought MY...

Wall Street mixed, Square jumps 10pc US stock markets were mixed overnight, as America’s top infectious disease doctor, Dr. Anthony Fauci, warned of “more pain and suffering ahead.” The Dow Jones fell by 0.28%, S&P 500 was down 0.18%, a...

PharmAust has had a busy and productive quarter, setting the foundations for the commercialisation of its lead drug, monepantel. Clinical stage biotech company, PharmAust (ASX:PAA), has had a very productive last quarter, making progress an...

Stockhead’s Q-Wrapz video series features one-on-one interviews showcasing the latest quarterly results of emerging ASX companies. In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Roger Aston, e...

While the focus has been largely on vaccines, PharmAust is trialling a pill that directly targets SARS-CoV-2. Today’s results are the next step towards a human clinical trial. Following its recent patent application, PharmAust (ASX:PAA) is...

Summary BHP Group (ASX:BHP) shares climb over 3% on Tesla nickel supply deal Adbri (ASX:ABC) signs a new long-term gas deal with Senex (ASX:SXY) Etherstack (ASX:ESK) signs A$11.6 million Samsung Carrier Deal The S&P/ASX200 is...

The patent filing today is another step forward for PharmAust towards commercialisation of monepantel for antiviral diseases, as the company works to fight different types of cancers, viral and neurological diseases. Clinical stage biotech...

Summary The S&P/ASX200 gained as much as 0.9%, crossing above its 20-day moving average.   The market rally was driven by firm global cues and strong buying in energy and material stocks. Seven of the 11 sectors were trading in th...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has lodged a patent application for the use of its lead drug monepantel in a range of viral diseases. The PCT (Patent Co-operative Treaty) patent is directed towards the use of monep...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Clinical-stage biotechnology company PharmAust (ASX:PAA) has executed a research services agreement with the Walter and Eliza Hall Institute in Melbourne to investigate the effects of monepantel on human T-lymphotrophic virus-1 infe...

The collaboration agreement today will expand PharmAust’s work on viruses and broaden the scope potential for Monepantel’s antiviral activity. Clinical stage biotechnology company, PharmAust (ASX:PAA), has just executed a Research Services...

PharmAust (ASX: PAA) will evaluate the impact of its monepantel (MPL) drug on the human t-lymphotropic virus-1 (HTLV-1) under a new research agreement with Melbourne’s Walter and Eliza Hall Institute. According to PharmAust, between 10 and...

Wall Street at fresh record highs All three key US benchmarks rose and reached fresh record highs on Friday, ahead of kick-off in earnings season. The Dow Jones was up by 1.30%, S&P 500 by 1.13%, and tech heavy Nasdaq by 0.98%. Bank sto...

Clinical-stage biotechnology company PharmAust (ASX:PAA) has announced that after formal testing monepantel tablets remain within specifications relevant for both veterinary and human clinical trials.

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The stability tests marks another key step on PharmAust’s path to commercialisation. Clinical oncology company PharmAust (ASX:PAA) continues to move towards commercialisation for its lead drug, Monepantel, being developed for the treatment...

Clinical-stage biotechnology company PharmAust (ASX: PAA) has reported positive results from ongoing product stability and shelf-life testing of its lead anti-cancer drug candidate monepantel in tablet form. Data from two independent studie...

The successful conclusion of its Phase II clinical trials has now opened the door to the Phase III stage, with commercialisation also in discussions. Clinical stage oncology company, PharmAust (ASX:PAA), has made major progress in its quest...

PharmAust Limited’s (ASX: PAA) clinical trials testing anti-cancer drug monepantel in canine lymphoma has successfully achieved phase two primary endpoints with administering veterinarians now wanting to move to phase three. The clinical st...

S&P 500 closed at record high again Wall Street closed Friday mostly on a high note, with the S&P 500 once again reaching an all-time high. The S&P 500 climbed by 0.33%, the Dow Jones rose by 0.69%, but tech heavy Nasdaq fell sl...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week It has been...

After securing ethics approval, PharmAust (ASX: PAA) is gearing up to begin a phase I clinical trial in the December quarter, which will assess its monepantel drug in patients with motor neurone disease. Ethics approval from Monash Health g...

The Phase I clinical trial of lead drug Monenpantel in humans is an exciting development after earlier announced encouraging pre-clinical studies. Clinical stage oncology company, PharmAust Limited (ASX:PAA), is set to commence the Phase I...